Ondas Holdings Inc. (ONDS) Stock Weekend Update: Latest News, Analyst Targets, and What Investors Should Watch Next

Ondas Holdings Inc. (ONDS) Stock Weekend Update: Latest News, Analyst Targets, and What Investors Should Watch Next

NEW YORK, Dec. 27, 2025, 7:45 a.m. ET — Market Closed (Weekend).

Ondas Holdings Inc. (NASDAQ: ONDS) is heading into the weekend after a sharp, high-volume selloff in the last regular session, keeping the stock firmly in the spotlight for momentum traders and longer-term defense-tech investors alike.

Shares of Ondas finished Friday’s session at $8.48, down about 7% on the day after trading roughly between the mid-$8s and low-$9s, with about 49 million shares changing hands—an unusually heavy print that underscores how crowded the trade has become into year-end positioning. [1]

Because U.S. markets are closed today (Saturday), investors now shift from “what moved the stock at 11:00 a.m.” to “what could move it before Monday’s open”—with Ondas facing a mix of bullish growth narratives, real operational catalysts, and very real dilution/volatility risks.

What’s driving ONDS right now

1) The last 24–48 hours: headline flow is mostly “market-driven,” not “company-driven”

In the past two days, the most widely circulated coverage hasn’t been a new Ondas contract announcement—it’s been reaction coverage tied to ONDS’ volatile tape, insider activity context, and institutional positioning.

  • Heavy-volume drop recap: MarketBeat summarized Friday’s decline and flagged the combination of high volatility, mixed ratings data, and insider selling context as part of the backdrop investors are digesting. [2]
  • New institutional position (Q3 filing coverage): MarketBeat also reported that Farther Finance Advisors LLC disclosed a new position of 270,145 shares (about $2.09 million in reported value) in a Q3 filing—one more data point suggesting institutions remain active in the name even amid sharp swings. [3]
  • Fresh bullish analysis: A Seeking Alpha commentary by James Foord (published Friday afternoon) argued that the U.S. drone market is approaching an “inflection point,” framing Ondas as a speculative, high-upside way to express that theme—while explicitly acknowledging dilution/execution risk. [4]
  • Valuation/momentum take: Simply Wall St published a valuation-focused piece (Dec. 25) highlighting the stock’s strong recent run and discussing a narrative-driven “fair value” framework that implies upside—while also noting execution and integration risks could quickly change the story. [5]

Net-net: the most recent 24–48 hour coverage is investor positioning + volatility commentary, not a brand-new press release. That matters, because when a stock is moving more on positioning than fundamentals, reversals can be fast.

Analyst targets and forecasts: “low-$10s” is the common neighborhood, but sources vary

Forecasts for ONDS cluster in a broadly bullish zone, though the exact “consensus” depends on which data provider you’re looking at and how many firms they include.

  • MarketBeat’s aggregated view shows a consensus price target of $10.43 and a “Moderate Buy” consensus rating. [6]
  • Investing.com lists an average target of $11.50 (with a stated range that includes $10 on the low end and $13 on the high end). [7]

Named analysts and firms recently on the record

If you’re looking for “real humans with real notes” (not anonymous sentiment meters), here are several identifiable calls that continue to shape how investors frame the stock:

  • Needham analyst Austin Bohlig raised Ondas’ price target to $12 and reiterated a Buy rating following investor meetings with management. [8]
  • Oppenheimer analyst Tim Horan upgraded Ondas to Outperform with a $12 price target (per Investing.com’s report). [9]
  • H.C. Wainwright initiated coverage with a Buy rating and a $12 target (reported by Investing.com). [10]

Important nuance: analyst targets are not short-term catalysts by themselves, but in a momentum name they can amplify moves—especially when liquidity is thinner around holidays.

The fundamental bull case Ondas keeps pointing investors to

Ondas’ core pitch is that it’s building a scaled defense and security autonomy platform (air + ground + counter-UAS), while also maintaining an industrial wireless business.

Growth guidance and backlog remain central

In its most recent quarterly update, Ondas reported record Q3 revenue of $10.1 million, raised its 2025 revenue target to at least $36 million, and set a preliminary 2026 revenue target of at least $110 million. The company also discussed backlog and demand momentum across key platforms. [11]

Those numbers are a big reason ONDS trades like a story stock: if the ramp hits, today’s valuation can look reasonable in hindsight; if it doesn’t, the market can re-rate brutally.

Near-term operational catalysts investors are watching into early 2026

Ondas has also been stacking tangible “program” and “platform” headlines that matter for forward revenue visibility:

  • Border-protection tender: Ondas said its autonomous systems unit was selected as prime contractor for a major program and expects an initial purchase order in January 2026, with a multi-phase effort that could culminate in deploying thousands of autonomous drones. [12]
  • Roboteam acquisition (ground robotics): Ondas announced it completed the acquisition of Roboteam, adding rugged tactical unmanned ground vehicles used by defense and security forces, and positioning the company to offer multi-domain autonomy (air + ground). [13]
  • Leadership / scaling: Ondas appointed Brigadier General Patrick Huston (Ret.) as Chief Operating Officer (while continuing as General Counsel), explicitly framing the move around operational scaling, acquisition integration, and expanding government/defense engagement. CEO Eric Brock highlighted Huston’s operational and procurement background in the announcement. [14]

The risk case: what can trip ONDS up from here

Ondas is not a sleepy “set it and forget it” industrial name. It’s a high-volatility defense-tech roll-up story, and that comes with specific risks investors tend to underestimate when the stock is ripping:

1) Dilution and share issuance mechanics are real, not theoretical

A key near-term item investors should understand before the next session: Ondas disclosed exchange agreements tied to its subsidiary structure that resulted in share issuance in December and contemplated additional issuance in early January.

Specifically, the company disclosed it issued 5,299,482 shares on Dec. 17, 2025, and expects to issue approximately 2,389,203 additional shares on Jan. 5, 2026 (based on a referenced pricing mechanism). It also stated it expects to record an estimated $56.6 million one-time, non-cash charge in Q4 related to the exchange. [15]

That’s the kind of detail that can matter for sentiment in a momentum stock—especially if traders start gaming the calendar around expected issuance dates.

2) Insider selling headlines can weigh on perception in a momentum tape

MarketBeat’s recent coverage also emphasized insider selling context (as reported through SEC disclosures), which can act as an accelerant for profit-taking when the stock is already moving fast. [16]

3) Execution and integration risk

Ondas is integrating multiple acquisitions and expanding across defense customers and geographies. The upside is a broader product stack; the downside is that integration friction can delay bookings-to-revenue conversion—particularly for government procurement cycles.

What investors should know before the next session

Since the exchange is closed, the actionable question becomes: what could change the setup before Monday?

Here are the main “pre-open” items investors typically monitor for ONDS specifically:

Watch the tone of Monday premarket trade (not just price). ONDS has recently traded with unusually high volume for its size; in names like this, premarket liquidity can exaggerate moves and set the emotional tone for the session.

Track any weekend or early-Monday filing/news surprises. For Ondas, that can include contract updates, acquisition integration milestones, or SEC filing headlines that momentum traders latch onto quickly.

Know the calendar catalyst: early January share issuance mechanics. The Jan. 5, 2026 issuance referenced in the company’s disclosure is a date some traders may price in ahead of time. [17]

Understand what the bull case is actually betting on. The optimistic narrative relies on scaling from current revenue levels toward management’s 2026 target and converting major programs (including initiatives expected to begin with January 2026 orders) into repeatable delivery. [18]

Bottom line

Ondas Holdings (ONDS) enters the weekend with the stock down sharply in the most recent session but still surrounded by a steady stream of bullish “defense autonomy” framing from analysts and commentators. The next move likely depends less on today’s silent weekend tape and more on whether Monday brings (1) renewed dip-buying on high volume or (2) continued de-risking into year-end and early-January dilution mechanics.

References

1. stockanalysis.com, 2. www.marketbeat.com, 3. www.marketbeat.com, 4. seekingalpha.com, 5. simplywall.st, 6. www.marketbeat.com, 7. www.investing.com, 8. www.tipranks.com, 9. www.investing.com, 10. www.investing.com, 11. ir.ondas.com, 12. ir.ondas.com, 13. ir.ondas.com, 14. ir.ondas.com, 15. ir.ondas.com, 16. www.marketbeat.com, 17. ir.ondas.com, 18. ir.ondas.com

Stock Market Today

  • Janux Therapeutics (JANX) Draws Wall Street Interest as TRACTr Progress Highlights Upside
    December 27, 2025, 8:06 AM EST. Janux Therapeutics, Inc. (NASDAQ: JANX) is attracting renewed attention from investors after a consensus buy signal and a wide gap between high and low price targets, signaling meaningful upside potential. Analysts report a 1-year upside range roughly from 249% to 948%, with Barclays trimming its target to $29 but keeping an Overweight stance as part of its 2026 outlook. In late December, JANX updated on its Phase 1 study of JANX008, an EGFR-targeted TRACTr therapy, noting completion of the Phase 1a dose-escalation and the start of expansion cohorts to optimize dosing across selected solid tumors including colorectal cancer, NSCLC, and SCLC. Janux is a California-based clinical-stage biopharma advancing cancer immunotherapies via TRACTr and TRACIr platforms. Investors should weigh upside against execution risk in early-stage programs.
NuScale Power Corporation (SMR) Stock: Friday’s Sharp Drop, Dilution Watch, and Analyst Targets Ahead of Monday’s Open
Previous Story

NuScale Power Corporation (SMR) Stock: Friday’s Sharp Drop, Dilution Watch, and Analyst Targets Ahead of Monday’s Open

New York Stock Exchange (NYSE) Weekend Outlook: S&P 500 Near 7,000 as Fed Minutes Loom and Year-End Trading Enters the Final Stretch
Next Story

New York Stock Exchange (NYSE) Weekend Outlook: S&P 500 Near 7,000 as Fed Minutes Loom and Year-End Trading Enters the Final Stretch

Go toTop